STXS

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.

Wall Street analysts forecast STXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STXS is 4.33 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Stereotaxis Inc revenue for the last quarter amounts to 7.46M USD, decreased -18.83 % YoY.

Stereotaxis Inc. EPS for the last quarter amounts to -0.07 USD, decreased -12.50 % YoY.

Stereotaxis Inc (STXS) has 139 emplpoyees as of January 10 2026.

Today STXS has the market capitalization of 234.25M USD.